Full text is available at the source.
The effect of semaglutide combined with metformin on liver inflammation and pancreatic beta-cell function in patients with type 2 diabetes and non-alcoholic fatty liver disease
Semaglutide and metformin's impact on liver inflammation and insulin-producing cell function in type 2 diabetes with fatty liver disease
AI simplified
Abstract
The combination of semaglutide and metformin resulted in significantly greater improvements in liver inflammation markers and pancreatic beta-cell function in patients with type 2 diabetes and non-alcoholic fatty liver disease.
- Liver inflammation markers, such as ALT and AST, were lower in the group receiving semaglutide and metformin compared to the group receiving metformin alone.
- The FIB-4 index indicated reduced fibrosis in patients treated with the combination therapy.
- Beta-cell function improved in the semaglutide group, as shown by a higher Matsuda index and oral disposition index.
- Glycemic control, measured by HbA1c levels, was better in patients taking the combination therapy.
AI simplified